News & Videos - APTOSE BIOSCIENCES INC.

...

Thinking about buying stock in Dolphin Entertainment, Hall of Fame Resort & Entertainment, Aptose Biosciences, Cinedigm, or Brainstorm Cell Therapeutics? PR Newswire NEW YORK, March 24, 2021 NEW YORK , March 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DLPN, HOFV, APTO, CIDM, and BCLI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. DLPN:...

...

Thinking about trading options or stock in Aptose Biosciences, Novavax, Inovio Pharmaceuticals, Ford Motor, or Carnival Corp? PR Newswire NEW YORK, June 29, 2020 NEW YORK , June 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APTO, NVAX, INO, F, and CCL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all...

...

...

...

...

...

...

...

...

...

NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Aptose Biosciences Inc. (NASDAQ: APTO ) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, 2017 at 5:00 PM Eastern Time. To listen to the event live or access a replay of the call - visit: https://www.investornetwork.com/company/23421 To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About...

NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Aptose Biosciences Inc. (NASDAQ: APTO) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 08, 2017 at 5:00 PM Eastern Time. To listen to the event live - visit: https://www.investornetwork.com/company/23421 Replay Information The replay will be available online at: https://www.investornetwork.com/company/23421 About Investor Network Investor Network (IN) is a financial content community, serving millions...

NEW YORK, NY / ACCESSWIRE / May 11, 2017 / Aptose Biosciences Inc. (NASDAQ: APTO ) will be discussing their earnings results in their Q1 Earnings Call to be held May 11, 2017 at 5:00 PM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/23421 . Replay Information The replay will be available online at https://www.investornetwork.com/company/23421 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of...

SAN DIEGO and TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, Senior Vice President and Chief Financial Officer, will participate in the upcoming Canaccord Genuity Rare Disease Biopharma 1x1 Day to be held on February...

Pauses APTO-253 to Elucidate Manufacturing Setback -- Company to Host Conference Call Today at 8:30 AM ET -- SAN DIEGO and TORONTO, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced it will prioritize its resources toward the development of CG’806, an oral preclinical compound being developed for patients with...

SAN DIEGO and TORONTO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Biotech Showcase TM 2017 Conference on Tuesday, January 10th at 9:00 a.m. PST in San Francisco, CA. Conference Presentation Details: Date:...

SAN DIEGO and TORONTO, Dec. 29, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today provided an update on the development of APTO-253, its investigational compound for acute myeloid leukemia (AML). The company has successfully manufactured multiple batches of a new drug product formulation for APTO-253, including a batch that has been stable...